2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethylsulfamide | 1174169-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethylsulfamide
• 英文别名: N-(2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethyl)sulfamide；N-{2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl}aminosulfonamide；quinazoline-4-piperidine sulfamide；6,7-Dimethoxy-4-[4-[2-(sulfamoylamino)ethyl]piperidin-1-yl]quinazoline
• CAS: 1174169-87-9
• 化学式: C₁₇H₂₅N₅O₄S
• 分子量: 395.483
• InChiKey: BFPJKUMKCZVVRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-氯-6,7-二甲氧基喹唑啉 在 盐酸 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2-(1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl)ethylsulfamide
  参考文献：
  名称：

  [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。

  公开号：

  WO2020190912A1

文献信息

• [EN] ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE-PHOSPHODIESTÉRASE (ENPP-1) ET UTILISATIONS DE CES DERNIERS
  申请人：MAVUPHARMA INC

  公开号：WO2019046778A1

  公开（公告）日：2019-03-07

  Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

  本文揭示了一种增强和促进体内I型干扰素产生的方法和化合物。在某些实施例中，本文所披露的化合物是ENPP-1抑制剂，药物组合物，以及用于治疗癌症或病毒感染的方法。
• Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1
  作者：Elsa Forcellini、Sophie Boutin、Carole-Anne Lefebvre、Elnur Elyar Shayhidin、Marie-Chloé Boulanger、Gabrielle Rhéaume、Xavier Barbeau、Patrick Lagüe、Patrick Mathieu、Jean-François Paquin

  DOI：10.1016/j.ejmech.2018.01.094

  日期：2018.3

  A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki < 105 nM against human NPP1.

  最近显示，胞外核苷酸焦磷酸酶/磷酸二酯酶-1（NPP1）促进主动脉瓣的矿化，因此，其抑制作用是一个重要的目标。喹唑啉-4-哌啶磺酰胺化合物（QPS1）已被描述为NPP1的特异性和非竞争性抑制剂。我们在此报告了使用QPS1作为先导化合物的新型喹唑啉-4-哌啶磺酰胺类似物的合成和体外抑制研究。在制备的26种衍生物中，发现有四种化合物 对人NPP1的K i <105 nM。
• [EN] IMINO SULFANONE INHIBITORS OF ENPP1<br/>[FR] INHIBITEURS IMINO SULFANONE DE L'ENPP1
  申请人：VOLASTRA THERAPEUTICS INC

  公开号：WO2021225969A1

  公开（公告）日：2021-11-11

  The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

  本公开涉及一般来说是对细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的抑制剂，其组合物以及使用所述化合物和组合物的方法。更具体地说，本公开涉及基于砜亚胺的ENPP1抑制剂，其化学式为（I），以及其用于治疗由ENPP1介导的疾病的方法。
• Quinoline and quinazoline compounds and methods of use thereof
  申请人：Stingray Therapeutics, Inc.

  公开号：US11407729B2

  公开（公告）日：2022-08-09

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

  化合物及其制备和用作治疗剂或预防剂的方法，例如通过靶向八核苷酸焦磷酸酶/磷酸二酯酶-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。
• Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design
  作者：Snahel D. Patel、Wendy M. Habeski、Alan C. Cheng、Elisa de la Cruz、Christine Loh、Natasha M. Kablaoui

  DOI：10.1016/j.bmcl.2009.04.006

  日期：2009.6

  PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis. We have identified a series of potent quinazolin-4-piperidin-4-ethyl sulfamide PC-1 inhibitors. The series, however, suffers from high affinity binding to hERG potassium channels, which can cause drug-induced QT prolongation. We used a hERG homology model to identify potential key interactions between our compounds and hERG, and the information gained was used to design and prepare a series of quinazolin-4-piperidin-4-methyl sulfamides that retain PC-1 activity but lack binding affinity for hERG. (C) 2009 Elsevier Ltd. All rights reserved.